IQVIA Holdings Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Life Sciences Tools and Services | Market Cap: ₹30.2K Cr
- Continued organic growth expected: 3% in R&D Solutions (R&DS) and 5% in Commercial Solutions, with overall enterprise growth around 4%. - Full-year 2026 revenue guidance reaffirmed at $17.15B to $17.35B, implying 5.2%-6.4% growth (5.8% midpoint). - Adjusted EBITDA guidance reaffirmed between $3.975B and $4.025B, with 4.9%-6.3% growth (5.6% midpoint). - Adjusted diluted EPS guidance raised to $12.65-$12.95, up 6.1%-8.6%, or 7.4% at midpoint. - Q2 2026 expected revenue between $4.28B and $4.34B, 6.5%-8.0% growth. - Q2 adjusted EBITDA expected at $955M-$975M, 4.9%-7.1% growth. - Q2 adjusted diluted EPS expected at $2.98-$3.08, 6.0%-9.6% growth. - FX tailwinds and acquisition effects factored into guidance. - Confidence in margin improvement due to productivity programs despite near-term mix/headwinds. - Organic growth: approx.
From IQVIA Holdings Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹181.09
Market Cap
₹30.2K Cr
P/E Ratio
20.1
Revenue Rank
Margin Rank
How does IQVIA Holdings Inc. rank in Life Sciences Tools and Services?
Compare IQVIA Holdings Inc. against every Life Sciences Tools and Services company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 4- →Continued organic growth expected: 3% in R&D Solutions (R&DS) and 5% in Commercial Solutions, with overall enterprise growth around 4%.
- →Revenue guidance for full year 2026: $17.15 - $17.35 billion, implying 5.2% to 6.4% growth, 5.8% at midpoint.
- →Second quarter 2026 revenue projected between $4.28 - $4.34 billion, representing 6.5% to 8.0% growth year-over-year.
- →Strong pipeline with record backlog of $34.2 billion in R&DS and significant next 12-month revenue conversion ($8.9 billion, up high single digits).
- →AI integration is a growth driver, expanding client adoption with 192 deployed AI agents covering 64 use cases, boosting efficiencies and enabling new offerings.
- →Commercial Solutions growth fueled by increased drug launches and innovation in AI-enabled analytics and consulting services.
- →Large pharma clients show renewed confidence, increasing pipeline assets with plans to double molecules, leading to more trials and demand.
- →Market demand stabilized and improving, though growth slower than pre-pandemic cruising altitude.
📈 Profitability & Margins
Rank 3- →Full-year 2026 revenue guidance reaffirmed at $17.15B to $17.35B, implying 5.2%-6.4% growth (5.8% midpoint).
- →Adjusted EBITDA guidance reaffirmed between $3.975B and $4.025B, with 4.9%-6.3% growth (5.6% midpoint).
- →Adjusted diluted EPS guidance raised to $12.65-$12.95, up 6.1%-8.6%, or 7.4% at midpoint.
- →Q2 2026 expected revenue between $4.28B and $4.34B, 6.5%-8.0% growth.
- →Q2 adjusted EBITDA expected at $955M-$975M, 4.9%-7.1% growth.
- →Q2 adjusted diluted EPS expected at $2.98-$3.08, 6.0%-9.6% growth.
- →FX tailwinds and acquisition effects factored into guidance.
- →Confidence in margin improvement due to productivity programs despite near-term mix/headwinds.
- →Organic growth: approx. 3% in R&DS segment, 5% in commercial segment, indicating solid operating performance.
🏗️ Capital Expenditure Plans
Yes- →First quarter capital expenditures were $127 million.
- →Free cash flow was strong at $491 million, representing 100% of adjusted net income, up 15% year-over-year.
- →No specific future capex guidance detailed beyond Q1.
- →The company is heavily investing strategically in AI capabilities across Commercial Solutions and R&D, deploying over 190 AI agents covering 50+ use cases.
- →Strategic collaborations have been established, such as with Duke Clinical Research Institute to advance clinical research, indicating ongoing investment in partnerships to enhance capabilities.
- →Repurchased $562 million of shares in Q1, showing allocation of capital towards shareholder returns.
- →No explicit mention of increased or planned capex beyond the stated Q1 amount and strategic AI development investments.
💰 Fundraising & Capital Structure
No information- →As of March 31, 2026, the company had cash and cash equivalents totaling $1.947 billion and gross debt of $15.83 billion, resulting in net debt of $13.886 billion.
- →The net leverage ratio stood at 3.62x trailing 12 months adjusted EBITDA.
- →There is no specific mention of any new or planned fundraising through debt or equity in the provided text.
- →The company repurchased $562 million of its shares in the first quarter, with approximately $1.2 billion of repurchase authorization remaining.
- →No indications or guidance about future fundraising activities through new debt or equity issuance were disclosed.
📋 Order Book & Pipeline
Yes- →Q1 2026 R&D Solutions net new bookings: $2.5 billion (double-digit YoY increase).
- →R&D Solutions backlog as of March 31, 2026: $34.2 billion (mid-single-digit YoY increase).
- →Next 12-month revenue from backlog: $8.9 billion (high single-digit YoY growth).
- →Book-to-bill ratio in Q1: 1.04 (despite unusually low pass-through bookings).
- →Qualified pipeline grew mid-single digits YoY; RFP flow grew high single digits YoY.
- →Commercial Solutions bookings strong, with AI-enabled offerings driving pipeline growth.
- →Note: Book-to-bill ratios vary quarterly and are not a reliable predictor of future growth.
- →Backlog represents revenue expected over the next 4-7 years, with a steady conversion rate.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Life Sciences Tools and Services this season
- Revvity, Inc. (Q2 FY26)
Revvity, Inc. Q2 FY26 quarterly results analysis. 2026 revenue guidance updated to $2.81 billion - $2.84 billion, with pro forma organic growth expected at 3% t
- Medpace Holdings, Inc. (Q2 FY26)
Medpace Holdings, Inc. Q2 FY26 quarterly results analysis. Revenue is expected to remain within the current guidance range for 2026 despite higher cancellations
- Illumina, Inc. (Q2 FY26)
Illumina, Inc. Q2 FY26 quarterly results analysis. Illumina expects continued strong momentum in clinical sales, projecting mid-teens growth for the clinical ma
- Mettler-Toledo International Inc. (Q2 FY26)
Mettler-Toledo International Inc. Q2 FY26 quarterly results analysis. The company expects local currency sales growth of approximately 4% for full year 2026, in
Frequently Asked Questions
What were IQVIA Holdings Inc. Q2 FY26 results?
- Continued organic growth expected: 3% in R&D Solutions (R&DS) and 5% in Commercial Solutions, with overall enterprise growth around 4%. - Full-year 2026 revenue guidance reaffirmed at $17.15B to $17.35B, implying 5.2%-6.4% growth (5.8% midpoint). - Adjusted EBITDA guidance reaffirmed between $3.975B and $4.025B, with 4.9%-6.3% growth (5.6% midpoint). - Adjusted diluted EPS guidance raised to $12.65-$12.95, up 6.1%-8.6%, or 7.4% at midpoint. - Q2 2026 expected revenue between $4.28B and $4.34B, 6.5%-8.0% growth. - Q2 adjusted EBITDA expected at $955M-$975M, 4.9%-7.1% growth. - Q2 adjusted diluted EPS expected at $2.98-$3.08, 6.0%-9.6% growth. - FX tailwinds and acquisition effects factored into guidance. - Confidence in margin improvement due to productivity programs despite near-term mix/headwinds. - Organic growth: approx.
What is IQVIA Holdings Inc. share price analysis?
IQVIA Holdings Inc. currently shows a neutral. The stock trades at a P/E of 20.1 with a market cap of $30,224. Investors should review the full earnings analysis for detailed insights.
Is IQVIA Holdings Inc. planning capital expenditure?
- First quarter capital expenditures were $127 million.
Keep IQVIA Holdings Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.